Wayne P. Yetter Joins SDIX Board of Directors
May 24,
2010
NEWARK, DE (May 24, 2010) – SDIX (Nasdaq: SDIX), a leading provider
of biotechnology-based products and services for a broad range of life
science, biotechnology, diagnostic, and food safety applications, today
announced Wayne P. Yetter has been elected to the Board of Directors,
effective May 18, 2010. Mr. Yetter is a member of Class II and his term
is scheduled to expire at the annual meeting of stockholders to be held
in 2012.
Mr. Yetter is currently Chief Executive Officer of
ProActive for Patients Media, Inc., an early investment stage company
providing a physician-to-patient messaging system to increase patient
adherence to medication therapies. Previously, Mr. Yetter served as
Chief Executive Officer of Verispan LLC, a joint venture of McKesson
Corp. and Quintiles Transnational, a leading provider of healthcare
information and marketing services to the pharmaceutical industry. Mr.
Yetter had a 30 year career in the pharmaceutical industry and held
executive positions at Pfizer, Merck, Astra-Merck (now AstraZeneca) and
Novartis. His roles included Vice President, Marketing Operations
(global) and Vice President, Far East and Pacific at Merck, founding
Chief Executive Officer of Astra-Merck, and President and Chief
Executive Officer of Novartis Pharmaceuticals Corporation, the US
division of Novartis AG. Mr. Yetter holds a B.A. in Biology from Wilkes
University and received an M.B.A from Bryant University.
“We are
excited to welcome Wayne to the SDIX board,” said Fran DiNuzzo,
President and CEO of SDIX. “His years of leadership experience in the
Life Science industry will add knowledge and insight to the SDIX board
and to our management team. We look forward to his contributions as we
continue to transition SDIX into a growth business.”
###
This
news release may contain forward-looking statements reflecting SDI's
current expectations. When used in this press release, words like
“anticipate”, “could”, “enable”, “estimate”, “intend”, “expect”,
“believe”, “potential”, “will”, “should”, “project”, “plan” and similar
expressions as they relate to SDI are intended to identify said
forward-looking statements. Investors are cautioned that all
forward-looking statements involve risks and uncertainties, which may
cause actual results to differ from those anticipated by SDI at this
time. Such risks and uncertainties include, without limitation, changes
in demand for products, the application of our technologies to various
uses, delays in product development, delays in market acceptance of new
products, retention of customers and employees, adequate supply of raw
materials, inability to obtain or delays in obtaining fourth party,
including AOAC, or required government approvals, the ability to meet
increased market demand, competition, protection of intellectual
property, non-infringement of intellectual property, seasonality, and
other factors more fully described in SDI's public filings with the U.S.
Securities and Exchange Commission.
SDIX
Company Contact:
Kevin Bratton
Chief Financial
Officer
(302) 456-6789
kbratton@sdix.com
About SDIX
SDIX is a biotechnology company, expert at creating advantage by providing a broad
range of quality, innovative and effective immuno-solutions to the Pharmaceutical,
Biotechnology, Diagnostics, and Food Safety markets. For 20 years, SDIX has
developed antibodies which advance its customers’ immuno-based work – reducing
time, labor, and costs while increasing accuracy and reliability of results.
SDIX offers a full suite of integrated immuno-solution capabilities including assay
design, development, and production. In life science markets, SDIX capabilities are
being used to help discover the mechanisms of disease, facilitate the development of
new drugs, and provide mechanisms for rapid diagnosis. For more information, visit
www.sdix.com.
Media Contact
Glenn Frantz
Director, Communications
SDIX
111 Pencader Drive
Newark, DE 19702
www.sdix.com
302-456-6789 (x 21345)
302-463-0625 (cell)
gfrantz@sdix.com